XM does not provide services to residents of the United States of America.
S
S

Sonova

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UBS starts Demant with 'buy', cuts Coloplast to 'sell'

BUZZ-UBS starts Demant with 'buy', cuts Coloplast to 'sell' ** UBS initiates coverage of medical devices maker Demant DEMANT.CO with "buy" rating, and downgrades its Danish peer Coloplast COLOb.CO to "sell" from "neutral" ** It sees Demant to deliver a 13% EPS compound annual growth rate (CAGR) for 2024-2028, ahead of both Swiss rival Sonova SOON.S
S

Accelleron, BHP, Kingfisher

EUROPE RESEARCH ROUNDUP-Accelleron, BHP, Kingfisher Aug 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Accelleron, BHP and Kingfisher, on Wednesday. HIGHLIGHTS * Accelleron ACLN.S : Deutsche Bank raises target price to CHF 42 from CHF 34 * BHP Group BHPB.L : JP Morgan cuts target price to 2,580p from 2,650p * Kingfisher KGF.L : Citigroup cuts to neutral from buy * Vonovia SE VNAn.DE : Citigroup raises target price to EUR 52.80 f
A
A
A
B
B
B
C
C
D
E
I
K
N
P
S
S
S
S
T
V
H
B
D

Jefferies says Demant nears valuation trough, ups to 'hold'

BUZZ-Jefferies says Demant nears valuation trough, ups to 'hold' ** Jefferies upgrades Danish hearing aid maker Demant DEMANT.CO to "hold" from "underperform" on low relative valuation, but notes an absence of catalysts for the stock ** It says Demant is nearing a trough in valuation, after Swiss rival Sonova SOON.S outperformed it over the past three months ** Demant's profit warning in July reflects the impact of its brand strategy in the U.S.
S

Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine

BUZZ-Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** JP Morgan raises UCB UCB.BR to "overweight" from "neutral" as it sees the Belgian biotech firm's "superior growth profile" as "significantly" undervalued by the market; cites expected acceleration in Bimzelx growth ** Morgan Stanley downgrades Sonova SOON.S to "underweight" from "equal-weight", flagging the hearing aid maker's EV/EBITA valua
M
S
U
V
V

Morgan Stanley upgrades hearing aid maker Demant, cuts peer Sonova

BUZZ-Morgan Stanley upgrades hearing aid maker Demant, cuts peer Sonova ** Morgan Stanley upgrades hearing aid maker Demant DEMANT.CO to "overweight" from "underweight", while downgrading its peer Sonova SOON.S to "underweight" from "equal-weight" ** Sees an attractive entry point for Demant, citing de-risked estimates after the profit warning and
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.